Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1

Conditions

Multiple Myeloma 186Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 41Recurrence 28Neoplasms, Plasma Cell 27Lymphoma 25Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 20Lymphoma, B-Cell, Marginal Zone 15Lymphoma, Non-Hodgkin 14Leukemia, Myeloid, Acute 13Smoldering Multiple Myeloma 9Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 7Lymphoma, B-Cell 7Waldenstrom Macroglobulinemia 6Neoplasms 6Neoplasm, Residual 6Immunoglobulin Light-chain Amyloidosis 6Lymphoma, T-Cell 5Leukemia, Plasma Cell 5Leukemia, Myelomonocytic, Chronic 5Renal Insufficiency 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Hematologic Diseases 4Sezary Syndrome 3

Interventions

X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2LY3023414 2Cyclophosphamide 2thymoglobulin 1fludarabine 1etoposide phosphate 1cobimetinib 1Whole-Body Irradiation 1Tacrolimus 1Sirolimus 1Rituximab 1Pharmacogenomic Variants 1Mycophenolic Acid 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Histiocytosis, Langerhans-Cell × Lenalidomide × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡